This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Harvey B. Niell, MD; Genaro M. Palmieri, MD; Charles L. Neely, Jr, MD; Martha W. McDonald, MD

Arch Intern Med. 1981;141(11):1471-1473.

Abstract
Postabsorptive urine hydroxyproline (HYPRO) excretion ("spot" HYPRO test) was compared with the 24-hour urine excretion of HYPRO in 45 patients with breast cancer and nine normal subjects on a low-gelatin diet. A good correlation was observed between the results of these two tests in both groups. Patients with skeletal metastasis showed a higher spot HYPRO value than those without bone involvement and the number of lesions by bone scanning correlated with the values of spot HYPRO. In 20 of 22 patients with bone metastasis followed up for three to 19 months, spot HYPRO values correlated well with the evolution of bone disease. We conclude that the spot HYPRO test is a simple, inexpensive, and accurate method for the diagnosis and follow-up of patients with skeletal metastasis from breast cancer.

(Arch Intern Med 1981;141:1471-1473)

Author Affiliations
From the Departments of Internal Medicine (Drs Niell, Palmieri, and Neely) and Nuclear Medicine (Dr McDonald), University of Tennessee Center for the Health Sciences, Memphis.

Footnotes
Accepted for publication Sept 29, 1980.

Reprint requests to Section of Oncology, Department of Internal Medicine, University of Tennessee Center for the Health Sciences, 800 Madison Ave, Memphis, TN 38163 (Dr Niell).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Total, Dialyzable, and Nondialyzable Postabsorptive Hydroxyproline: Values in Patients With Cancer
Niell et al.
Arch Intern Med 1983;143:1925-1927.
ABSTRACT